Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 415Cytarabine 337fludarabine phosphate 231Rituximab 206Methotrexate 199fludarabine 196venetoclax 174Azacitidine 174Busulfan 169Filgrastim 145Whole-Body Irradiation 143Mycophenolic Acid 143Peripheral Blood Stem Cell Transplantation 141Tacrolimus 138Etoposide 130Vincristine 113Melphalan 110Dexamethasone 110Cyclosporine 102Granulocyte Colony-Stimulating Factor 100Imatinib Mesylate 94Daunorubicin 91Antilymphocyte Serum 91Radiotherapy 84Decitabine 83Dasatinib 76Lenalidomide 75Doxorubicin 71Prednisone 69Idarubicin 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × PT-100 dipeptide × Other hematologic neoplasm × Clear all
NCT00086203 2015-03-25

Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

FDA Office of Orphan Products Development

Phase 2 Completed
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡